Biomarker

MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target Discovery

Retrieved on: 
Monday, June 5, 2023
Research, Finance, Professional Services, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Genomics, BMY, CRISPR, Silicon, Cancer, Drug development, Bristol Myers Squibb, Gene, NYSE, Biomarker, Medic, Pharmaceutical industry

MEDiC Life Sciences (“MEDiC”), a Silicon Valley biotech startup, today announced that it entered into a research collaboration with Bristol Myers Squibb (NYSE:BMY).

Key Points: 
  • MEDiC Life Sciences (“MEDiC”), a Silicon Valley biotech startup, today announced that it entered into a research collaboration with Bristol Myers Squibb (NYSE:BMY).
  • In the collaboration, MEDiC is using its scalable 3-dimensional tumor models to perform CRISPR functional genomics screens in solid tumor indications of interest to Bristol Myers Squibb.
  • MEDiC is also using its immune cell and tumor cell co-culture platform to identify novel genes relevant to immune cell killing of cancer cells.
  • “We are very excited that Bristol Myers Squibb selected MEDiC as a collaborator to advance its oncology discovery programs,” said Kyuho Han, Ph.D., co-founder and chief executive officer of MEDiC.

Treos Bio Announces Presentation of Final Results from Phase 1b Study of PolyPEPI1018 Immunotherapy for Late-Stage Metastatic Colorectal Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Antigen, Mayo Clinic, Liver disease, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Vaccination, MSS, OS, Clinical Cancer Research, Biomarker, Immunotherapy, PFS, PBMC, CD8, ELISA, ASCO, NLM, American Society of Clinical Oncology, Patient, Immunoglobulin G, LM, Annual general meeting, HR, Neoplasm, Research, MOS, Society, Safety, Data science, Pharmaceutical industry, Vaccine, Medical imaging, Palm Treo

PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.

Key Points: 
  • PolyPEPI1018 is an off-the-shelf, multi-peptide vaccine derived from seven tumor associated antigens frequently expressed in patients with mCRC.
  • Final results from the study, conducted by Mayo Clinic in Minnesota, demonstrate that PolyPEPI1018 in combination with TAS-102 improved progression free-survival (PFS) and overall survival (OS) compared to historical data for standard of care TAS-102 alone.
  • “Importantly, these results show consistency between immunological responses and efficacy, and a particularly enhanced benefit in patients without liver metastasis.
  • Final results from the study demonstrate that PolyPEPI1018 and TAS-102 were safe and tolerable in combination with safety and toxicity profiles similar to TAS-102 monotherapy.

Altoida Appoints Marc Jones as Chief Executive Officer

Retrieved on: 
Monday, June 5, 2023
Software, Research, Other Health, Pharmaceutical, Data Management, Consumer, Technology, Clinical Trials, Science, Biotechnology, Seniors, Health, Other Science, International Rectifier, Drug development, International, Fresenius (company), Alzheimer's disease, Southern New Hampshire University, Multimedia, DSM-IV codes, Biomarker, History, Sale, MS, Genetics, Invitae, Machine learning, Jones, CFO, IVD, FDA, Investment, Fortune 500, Merck Group, NYSE, Security (finance), Medical imaging, Northeastern University

Altoida, Inc , a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today the appointment of industry veteran Marc Jones as Chief Executive Officer.

Key Points: 
  • Altoida, Inc , a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today the appointment of industry veteran Marc Jones as Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230605005214/en/
    "We are thrilled that Marc is joining Altoida as CEO, as the company transitions from clinical proof-of-concept to its commercial expansion phase,” said William (Bill) Moffitt, Chairman of the Board, Altoida.
  • “Marc is a visionary executive with a proven track record of successfully guiding healthcare companies through important commercial milestones.
  • These technologies have the potential to revolutionize drug development in neurological clinical trials along with treatment and care for individuals affected by neurological diseases,” said Marc Jones, CEO, Altoida.

OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore for the Treatment of Obesity and Associated Diseases

Retrieved on: 
Monday, June 5, 2023
Hospitals, Genetics, Diabetes, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, PK, Insulin resistance, Yale School of Medicine, FRCP, Obesity, Prevalence, NASH, Liver disease, Weight loss, Yale school, Biomarker, MACE, De novo, MACP, Doctor of Philosophy, DSM-IV codes, Plasma, Phase 1, MD, Cancer, Liver, Fatty liver disease, Human, Safety, Pharmaceutical industry, Dietary supplement, Medicine

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced completion of the second cohort of subjects in an ongoing Phase 1 trial of TLC-6740, a liver-targeted mitochondrial protonophore.
  • The first-in-human, Phase 1 study is exploring the safety and efficacy of TLC-6740 as an oral, first-in-class, liver-targeted mitochondrial protonophore for the treatment of obesity and obesity-associated diseases, including diabetes and nonalcoholic steatohepatitis (NASH).
  • “This first-in-human study is an important milestone for OrsoBio as we continue to advance our pipeline with this third program progressing to the clinic.
  • “By increasing energy expenditure, TLC-6740 is a promising complement to GLP-1 receptor agonists for obesity and offers the potential to improve obesity-associated comorbidities, including diabetes and NASH.”

Olaris, Inc. debuts novel global QqQ LC mass spectrometry panel for clinical metabolomics applications at the American Society for Mass Spectrometry 2023 Meeting

Retrieved on: 
Monday, June 5, 2023
Pharmacy, American Society for Mass Spectrometry, Drug development, ASMS, QQQ, NMR, Mass spectrometry, Research, Biomarker, Metabolome, MS, Machine learning, Metabolomics, Medicine, Annual general meeting, Society, Medical imaging

FRAMINGHAM, Mass., June 5, 2023 /PRNewswire-PRWeb/ -- Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company's research on developing a triple-quadrupole (QqQ) mass spectrometry (MS) platform for clinical metabolomics applications has been selected for a poster presentation on June 5th at the upcoming American Society for Mass Spectrometry (ASMS) 2023 Annual Meeting, to be held June 4th-8th in Houston, TX.

Key Points: 
  • Combined with their existing high-field multidimensional NMR technology, the new Olaris QqQ panel enables global, quantitative reproducible measurements of hundreds of metabolites for clinical and biopharmaceutical research.
  • "The new QqQ technology will expand our ability to detect clinically impactful changes in metabolites.
  • Yet due to challenges with analytical measurements and reproducibility concerns, metabolomics has yet to reach its full potential in diagnostic and drug development.
  • For more information on the ASMS meeting or to view the Olaris presentation during the conference, visit http://www.asms.org .

Olaris, Inc. to present data on metabolomic changes observed during DCD heart perfusion prior to successful transplant at the American Transplant Congress 2023 Meeting

Retrieved on: 
Monday, June 5, 2023
Heart, Surgeon, MGH, Surgery, Perfusion, DRS, Research, Biomarker, Ischemia, Patient, DCD, Machine learning, Metabolomics, Medicine, Annual general meeting, Reperfusion, Hospital, ATC, Transplant, Massachusetts General Hospital, Metabolite, Heart transplantation, Dentistry, Medical device

FRAMINGHAM, Mass., June 5, 2023 /PRNewswire-PRWeb/ -- Olaris, Inc., a precision medicine company leveraging metabolomics and machine learning to discover and develop its myOLARIS™ diagnostics products, is pleased to announce that the company's study on the metabolic changes occurring in donor hearts after Donation after Circulatory Death (DCD) heart transplant has been selected for a poster presentation on June 5th at the upcoming American Transplant Congress (ATC) 2023 Annual Meeting, to be held June 3rd-7th in San Diego, CA.

Key Points: 
  • Metabolite reprogramming observed in donor hearts after circulatory death and prior to transplant suggests exciting possibility for improved biomarkers to assess DCD heart quality.
  • The ATC 2023 presentation will describe data from a multi-year collaboration between Olaris and an elite team of heart transplant surgeons and researchers at Massachusetts General Hospital, including Drs.
  • The collaboration was formed with the goal of identifying biomarkers of heart damage due to ischemia and reperfusion during DCD heart transplant.
  • They found that several metabolites were consistently altered over time, reflecting metabolic reprogramming in the DCD hearts during machine perfusion.

BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
OTC Markets Group, CSE, McCormick Place, CSO, Development of the human body, Risk assessment, Lung cancer, FSE, Research, Biomarker, BUX, ASCO, Plasma, American Society of Clinical Oncology, Patient, Standard BioTools, Cancer, Annual general meeting, Poster, Society, Medical imaging

BioMark's blood-based metabolomic biomarker panel clinically improved early-stage lung cancer detection through stage shifting.

Key Points: 
  • The poster will also be available on our website following the conclusion of the meeting.
  • "The blood-based metabolites panel validated on our current retrospective study yielded sensitivity of 91% and specificity over 78% for all resectable lung cancer detection.
  • "We remain focused and committed in the commercialization of this important molecular assay that addresses a significant need in improving cancer management related in early lung cancer detection.
  • BioMark is poised to take it's blood-based metabolomic biomarker panel to the next level and bring new hope to people at high risk of developing lung cancer."

Rockley Photonics Completes Financial Restructure, Emerges from Chapter 11

Retrieved on: 
Monday, June 5, 2023
Science, Biometrics, Biotechnology, Research, Health, Diabetes, Wearables, Mobile Technology, Technology, Chapter 11, Title 11, United States Code, Glucose, Innovation system, OBE, Multimedia, Biomarker, Hypertension, Medtronic, Diagnosis, Growth, Photonics, Disease, Renewable energy, Rockley

Rockley Photonics today announced that it has completed a comprehensive financial restructuring and emerged from Chapter 11 after filing for bankruptcy protection in Q1.

Key Points: 
  • Rockley Photonics today announced that it has completed a comprehensive financial restructuring and emerged from Chapter 11 after filing for bankruptcy protection in Q1.
  • View the full release here: https://www.businesswire.com/news/home/20230605005121/en/
    Andrew Rickman, Ph.D., OBE – Rockley Photonics CEO and Executive Chairman (Photo: Business Wire)
    All of Rockley’s material customer relationships remain in place.
  • Rockley continues to see promising results relating to a number of biomarkers, including glucose, and anticipates releasing those results in the second half of this year.
  • Within this field, cuff-less blood pressure monitoring emerges as a particularly promising growth engine.”

Thermo Fisher Scientific Introduces Groundbreaking Mass Spectrometer to Revolutionize Biological Discovery

Retrieved on: 
Monday, June 5, 2023
Science, Other Science, Other Manufacturing, Finance, Professional Services, Technology, Manufacturing, Other Technology, Astral, American Society for Mass Spectrometry, University, ASMS, Mass spectrometry, George R. Brown Convention Center, Cardiovascular disease, Cancer, TMO, Proteomics, Proteome, Multimedia, Research, Thermo Fisher Scientific, Genomics, Biomarker, Thermo, Laboratory, University of Washington Department of Global Health, Medicine, Health, Mindful Scientific Inc., Society, NYSE, Disease, Medical imaging, Orbitrap

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer , one of the most significant advancements in mass spectrometry in 15 years.
  • Researchers can use this information to identify new clinical biomarkers, reveal diseases earlier and develop new interventions for everything from cardiovascular disease to cancer.
  • View the full release here: https://www.businesswire.com/news/home/20230605005016/en/
    The Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer offers accurate and precise quantitation in proteomics laboratories with faster throughput, deeper coverage and higher sensitivity than the current state-of-the-art.
  • “The Orbitrap Astral mass spectrometer is a true gamechanger, offering an unrivaled combination of sensitivity, dynamic range and speed that doesn’t compromise accurate and precise quantitation.

Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update

Retrieved on: 
Monday, June 5, 2023
EASL, Pitango, Therapy, NASH, Norwest Venture Partners, Adi, Journal of Accounting and Economics, Clinical trial, CMMB, General partnership, Physiology, MBA, Biomarker, Certified Public Accountant, Doctor of Philosophy, Economics, Health care efficiency measures, Congress, TEL, Data analysis, MD, Patient, Investment, Biophysics, Fattal, Fatty liver disease, CFO, Knowledge, Growth, PSC, Systemic scleroderma, BA, Autoimmunity, Inflammation, Management, Pharmaceutical industry, Finance, Tel Aviv University, Accounting

(Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.

Key Points: 
  • (Nasdaq: CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced changes to its executive leadership team and provided a corporate update.
  • "I am excited to resume my corporate leadership responsibilities and look forward to continued engagement with our key stakeholders," said Dr. Mor.
  • "This transition of executive leadership to the company's founding team will focus on maintaining business continuity and ensuring clinical plan execution," continued Dr. Mor.
  • Adi's exceptional corporate leadership skills are complemented by her extensive knowledge in autoimmune, inflammatory and fibrotic diseases and broad experience in developing monoclonal antibodies.